Investigating Genomic Mechanisms of Treatment Resistance in Castration Resistant Prostate Cancer
Annual summary 1 May 2012-30 Apr 2013
CALIFORNIA UNIV SAN FRANCISCO
Pagination or Media Count:
The purpose of this work is to better understand the mechanisms of resistance to androgen biosynthesis inhibitors in men with castration resistant prostate cancer, and to investigate clinical methods of overcoming resistance. Key Accomplishments and Findings to date CTCs collected in 12 men with abiraterone-na ve mCRPC. These cells are in the process of enumeration, immunocytochemical analysis for expression of prostatespecific cell surface markers, and DNA isolation. CTCs thus far are detectable in 90 of men using the Vitatex VitaCaP assay. CTCs expressing a mesenchymal phenotype are detectable as well as those bearing markers of stemness including CD44. CTCs from this assay are amenable to flow cytometry both for enumeration and for sorting of different CTC subpopulations. Further genomic analysis of CTC subpopulations to be detailed in subsequent updates. Phase II protocol for Dose- Increased Abiraterone Acetate in Men with mCRPC PI Friedlander written, IRB approved, and accruring patients at by UCSF and Oregon Health Sciences University. Phase II protocol of Abiraterone Acetate plus ARN-5 09 in men with mCRPC PI Friedlander completed, approved by UCSF site-review committee, and in further development at UCSF and at Dana Farber Cancer Institute. Integration of both clinical trials with recently awarded Stand Up 2 Cancer West Coast Dream Team castration-resistant prostate cancer biopsy protocol, allowing for even more comprehensive molecular and genomic analysis of mechanisms of abirateroneABI resistance.
- Anatomy and Physiology
- Medicine and Medical Research